About Jupiter Endovascular
Jupiter Endovascular is a company based in Menlo Park (United States) founded in 2024. Jupiter Endovascular has raised $61 million across 2 funding rounds from investors including Senvest Capital, LB Investment and Sonder Capital. Jupiter Endovascular offers products and services including Endoportal Control and Vertex Pulmonary Embolectomy System. Jupiter Endovascular operates in a competitive market with competitors including Instylla, Spectrum Vascular, Access Point Technologies, Ridgeback Technologies and SlipStream Medical, among others.
- Headquarter Menlo Park, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$61 M (USD)
in 2 rounds
-
Latest Funding Round
$40 M (USD), Series B
Oct 07, 2025
-
Investors
Senvest Capital
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Jupiter Endovascular
Jupiter Endovascular offers a comprehensive portfolio of products and services, including Endoportal Control and Vertex Pulmonary Embolectomy System.
Technology merging surgical precision with catheter interventions for treatments.
System for treating pulmonary embolism through controlled endovascular procedures.
People of Jupiter Endovascular
Unlock access to complete
Unlock access to complete
Funding Insights of Jupiter Endovascular
Jupiter Endovascular has successfully raised a total of $61M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $40 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Jupiter Endovascular
Jupiter Endovascular has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Senvest Capital, LB Investment and Sonder Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage medtech startups are invested in by Sonder Capital.
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by this private equity firm.
|
Locked | Locked | Locked | |
|
Growth-stage private equity investments are targeted across multiple sectors.
|
Locked | Locked | Locked |
Investor details for Jupiter Endovascular
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Jupiter Endovascular
Investment portfolio details for Jupiter Endovascular
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Jupiter Endovascular
Detailed financials for Jupiter Endovascular
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Jupiter Endovascular Comparisons
Peer comparison for Jupiter Endovascular
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Jupiter Endovascular
Jupiter Endovascular operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Instylla, Spectrum Vascular, Access Point Technologies, Ridgeback Technologies and SlipStream Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Hydrogel technology is developed for embolization therapy applications.
|
|
| Locked | Locked | Locked |
Vascular access medical devices are developed by Spectrum Vascular.
|
|
| Locked | Locked | Locked |
A range of EP diagnostic and ablation catheters is developed.
|
|
| Locked | Locked | Locked |
Catheter balloons are developed with short lead times.
|
|
| Locked | Locked | Locked |
Manufacturer of catheter insertion device
|
Detailed competitors of Jupiter Endovascular
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Jupiter Endovascular
Complete news archive for Jupiter Endovascular
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jupiter Endovascular
Jupiter Endovascular was founded in 2024.
Jupiter Endovascular is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Carl St Bernard is the current CEO of Jupiter Endovascular.
Jupiter Endovascular is a funded company, having raised a total of $61M across 2 funding rounds to date.
Jupiter Endovascular was founded in 2024 and is based in Menlo Park, United States. Focus is placed on the development of minimally invasive medical devices within the endovascular intervention sector. The endoportal procedure is being advanced as a novel approach to endovascular interventions, incorporating Endoportal Control for improved precision and control in catheter-based methods. Operations center on innovation in device technology for vascular applications.
Jupiter Endovascular's top competitors include Instylla, Spectrum Vascular and Ridgeback Technologies.
Jupiter Endovascular offers Endoportal Control and Vertex Pulmonary Embolectomy System.
Jupiter Endovascular has 3 investors. Key investors include Senvest Capital, LB Investment, and Sonder Capital.